vTv Therapeutics

VTVT

Market cap $150M

38.98 USD

+1.01

2.66%

At close Updated Dec 30, 4:00 PM EST

1 day

2.66%

5 days

7.98%

1 month

65.87%

3 months

66.94%

6 months

159.87%

Year to date

187.25%

1 year

179.03%

5 years

-49.51%

10 years

-85.77%

About: vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.

Employees: 23

Healthcare Biotechnology